Roche lifts 2019 outlook as first-quarter sales beat forecasts By Reuters

© Reuters. FILE PHOTO: Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

ZURICH (Reuters) – Swiss drugmaker Roche raised its 2019 outlook after first-quarter sales beat analyst forecasts on the strength of newer medicines including multiple sclerosis treatment Ocrevus and cancer immunotherapy Tecentriq.

Roche said sales are now expected to grow in the mid-single digit range, at constant exchange rates.

Revenue in the first quarter rose to 14.8 billion Swiss francs ($14.70 billion), compared to the 14.2 billion franc average forecast in a poll for Reuters. Ocrevus sales rose 67 percent to 836 million francs. Tecentriq revenue more than doubled to 336 million francs.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.